🔗 Share this article

An underground market for unlicensed weight-loss drugs is being driven by social media fitness personalities and vendors on messaging platforms, based on recent findings.

Investigational Drug Acquiring Traction Via Social Media

Retatrutide, which remains in clinical trials, is being promoted by social media influencers for its alleged fat-burning properties. Followers are urged to contact these accounts directly for supplier links, while also obtaining discount codes.

Active Trade on Social Networks

Additionally, a robust trade exists on messaging services, where communities with thousands of participants share “before and after” images, injection guides and assertions of next-day UK delivery. Sellers promote the substance there before redirecting customers to other platforms for transactions.

Understanding The Experimental Drug

Retatrutide is an investigational injectable created by American pharmaceutical company Eli Lilly. The treatment affects three gut hormones – glucagon-like peptide-1, GIP and glucagon. Early trials indicate it could assist patients reduce up to a quarter of their body weight. Nicknamed the “triple G”, the substance is being hailed digitally as the successor to Ozempic.

Healthcare Experts Voice Concerns

However, physicians and pharmacists have cautions that the sale of what remains an unlicensed drug in the United Kingdom is worrisome and could result in individuals administering products of uncertain source.

Some experts said the popularity for the experimental drug could be linked to the increasing price of licensed slimming treatments such as Mounjaro.

Legal Position and Implementation

Marketing retatrutide on social media or messaging apps is illegal in the UK, as it is an unlicensed medication that cannot be marketed or distributed for personal consumption under the Human Medicines Regulations 2012.

Some influencers try to circumvent the regulations by calling to the drug as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a restricted drug, but advertising and supply can still breach medicines, marketing, and customer laws, potentially leading to penalties, legal action or prison.

Platform Response and Content Elimination

According to the social media company, the service has removed problematic material and banned associated keywords and search suggestions. The company stated it was committed to maintaining the platform secure and investing in strengthening enforcement strategies.

Digital Marketplace Operations

Research also found communities with up to 9,000 participants marketing the experimental drug using Telegram's integrated discovery tool, which functions like a online catalog. Entering “retatrutide” immediately brings up groups with numerous of members, filled with images of slimming results, positive reviews and step-by-step instructions for preparing or injecting at home.

Within minutes of joining one group, a vendor shared contact information, where most purchases occur. The seller sent an instruction manual and guaranteed delivery within 48 hours. When asked whether the product was authentic, one vendor responded: “You can’t be sure.” Another shared a image of a alleged testing documentation. None asked about weight, health issues or previous experience.

Product Details and Costs

Inside these groups, messages show black plastic parcels with Royal Mail labels, claiming to include new batches. One communication stated: “It took eight of us to load them this morning.”

Buyers can choose between dry substance containers, prepared at home with sterile water, or pre-filled pens typically priced at 160 pounds for 20 milligrams. When questioned how much time a pen should last, sellers give conflicting responses ranging from a several days to “depends on your body”.

Service Oversight and Security Measures

A spokesperson for the messaging service said it actively monitored harmful material on its service including material that promoted the “misuse of controlled medications”. The organization added that it eliminated “millions of pieces of harmful content each day”.

Healthcare Expert Warnings

“Individuals are administering materials they cannot confirm. Although the research behind retatrutide is sound, these online versions may not contain what they claim,” said Jason Murphy, the head of pharmacy at a pharmacy service.

Dr Crystal Wyllie of Asda Online Doctor linked the increase in demand to recent cost increases for approved weight-loss drugs such as Mounjaro. “With prices rising, individuals are turning to social media. But fake treatments are extremely risky. You can’t be certain what’s inside or whether the environment they were made in was clean,” she said.

Her staff has already encountered patients injured by self-injection from unverified suppliers. “We recognize the disappointment, but purchasing from Telegram or WhatsApp is gambling with your well-being,” said the doctor. “These materials could be contaminated or incorrectly dosed.”

Producer Position

A spokesperson from the pharmaceutical company stated retatrutide was in third stage clinical trials and had not been reviewed or authorized by any regulatory agency globally. “Therefore at this point no one can sell [it] for personal consumption,” they said, adding that any product “misleadingly claiming itself as a Lilly experimental product not yet authorized … may expose patients to potentially significant health risks”.